Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05718791
Other study ID # hhf
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 10, 2023
Est. completion date March 30, 2026

Study information

Verified date April 2024
Source Henry Ford Health System
Contact shatha farhan, MD
Phone 3137133910
Email sfarhan1@hfhs.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date March 30, 2026
Est. primary completion date March 30, 2026
Accepts healthy volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Patients >18 year old admitted for allo SCT PB for malignant disease.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
blood sample
blood sample to check CXCL9 and EASIX at day 28 post stem cell transplant

Locations

Country Name City State
United States Henry Ford Health System Detroit Michigan

Sponsors (1)

Lead Sponsor Collaborator
Henry Ford Health System

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary predictors of acute GVHD CXCL9 combined with EASIX can be used as predictors of acute GVHD CXCL9 combined with EASIX calculated at day 28 +/- 2 post SCT can be used as predictors of acute GVHD by day 100.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05855707 - Wharton Jelly Mesenchymal Stromal Cells as GVHD Prophylaxis Phase 1
Active, not recruiting NCT04522843 - Analysis of Intestinal Defensin Expression in Acute GVHD
Recruiting NCT05401955 - Physiotherapy and Therapeutic Exercise Program in Graft-versus-host Disease (GvHD) N/A
Recruiting NCT05368181 - MAP-guided Preemptive Therapy of aGvHD Phase 2
Withdrawn NCT05443464 - Mesenchymal Stem Cells (MSCs) for Steroid Refractory Acute GVHD (SR-aGVHD) Phase 1
Not yet recruiting NCT06315309 - Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant Phase 2
Terminated NCT04220632 - A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease Phase 1/Phase 2
Recruiting NCT04284904 - Role of aGVHD Biomarkers on aGVHD Risks
Not yet recruiting NCT06164288 - Safety and Efficacy Study of hAESCs Therapy for aGVHD Phase 1
Recruiting NCT06462365 - Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) Phase 1